Multifactorial intervention for the prevention of vascular complications of type 2 diabetes

Hellenic Journal of Cardiology

Volumn 50, Issue 6, 2009, Pages 445-448

  Mitsiou, Eydoxia K ^a   Tziomalos, Konstantinos ^a   Anagnostis, Panagiotis ^b   Karagiannis, Asterios ^a   Athyros, Vasilios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

ACCORD; ADVANCE; Macrovascular complications; Multifactorial approach; Myocardial infarction; Stroke; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; ATORVASTATIN; GLICLAZIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; METFORMIN; PERINDOPRIL; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

ARTERY DISEASE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; EDITORIAL; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; STROKE;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 73249114072     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ. 2001; 322: 1389-1393.
2. Pyrgakis VN. The treatment of stable coronary artery disease in diabetics: the battle between "conservative" and "invasive" continues. Hellenic J Cardiol. 2009; 50: 341-342.
3. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373: 929-940.
4. Andrikopoulos G, Pipilis A, Goudevenos J, et al. Epidemiological characteristics, management and early outcome of acute myocardial infarction in Greece: the HELlenic Infarction Observation Study. Hellenic J Cardiol. 2007; 48: 325-334.
5. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007; 147: 149-155.
6. Rautio A, Lundberg V, Messner T, Nasic S, Stegmayr B, Eliasson M. Favourable trends in the incidence and outcome of myocardial infarction in nondiabetic, but not in diabetic, subjects: findings from the MONICA myocardial infarction registry in northern Sweden in 1989-2000. J Intern Med. 2005; 258: 369-377.
7. Pissimissis EG, Garoufalis SE. Prognosis and management of diabetic patients with acute coronary syndrome. Hellenic J Cardiol. 2005; 46: 139-147.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood- glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589.
11. Patel A, MacMahon S, Chalmers J, et al. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.
12. Patel A, MacMahon S, Chalmers J, et al. The ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829-840.
13. Gerstein HC, Miller ME, Byington RP, et al. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
14. Pastromas S, Koulouris S. Thiazolidinediones: antidiabetic drugs with cardiovascular effects. Hellenic J Cardiol. 2006; 47: 352-360.
15. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-2471.
16. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009; 32: 675-690.
17. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-2135.
18. Mancia G. Defining blood pressure goals: is it enough to manage total cardiovascular risk? J Hypertens. 2009; 27 Suppl 5: S3-8.
19. Zoungas S, de Galan BE, Ninomiya T, et al. On behalf of the ADVANCE Collaborative Group. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 2009; 32: 2068-2074.
20. Ostergren J, Poulter NR, Sever PS, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens. 2008; 26: 2103-2111.
21. Athyros VG, Ganotakis ES, Bathianaki M, et al. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol. 2005; 46: 380-386.
22. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-696.
23. Athyros VG, Papageorgiou AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology. 2003; 54: 679-690.
24. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29: 1220-1226.
25. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-393.
26. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-591.
27. Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjornsdottir S; Swedish National Diabetes Register. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diab Res Clin Pract. 2009; 86: 74-78.